Soligenix Inc. (SNGX) |
|
2 0.06 (3.09%)
|
09-20 20:46 |
|
Open: |
1.96 |
Pre. Close: |
1.94 |
|
High:
|
2.04 |
Low:
|
1.93 |
|
Volume:
|
380,455 |
Market Cap:
|
60M |
|
|
|
|
Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare disease. The company is headquartered in Princeton, New Jersey and currently employs 14 full-time employees. The firm is focused on developing and commercializing products to treat rare diseases. The firm operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.033 - 2.043 |
2.043 - 2.052 |
|
Low:
|
1.937 - 1.947 |
1.947 - 1.956 |
|
Close:
|
1.954 - 1.971 |
1.971 - 1.985 |
|
Technical analysis |
as of: 2020-09-18 4:35:44 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 2.44  One year: 2.69 |
| Support: |
Support1: 1.75 Support2: 1.46 |
| Resistance: |
Resistance1: 2.09 Resistance2: 2.30 |
| Pivot: |
1.93 |
| Moving Average: |
MA(5): 1.94  MA(20): 1.98
MA(100): 1.96 MA(250): 1.76 |
| MACD: |
MACD(12,26): -0.06 Signal(9): -0.07 |
| Stochastic oscillator: |
%K(14,3): 48.48 %D(3): 42.80 |
| RSI: |
RSI(14): 47.96 |
| 52-week: |
High: 3.54 Low: 0.85 Change(%): 118.9 |
| Average Vol(K): |
3-Month: 126391 10-Days: 31943 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.SNGX has closed below upper band by 35.5%. Bollinger Bands are 38% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Tue, 15 Sep 2020
Soligenix, Inc. (SNGX) Reports Publication Demonstrating Thermostabilization of Filovirus Vaccine Antigens - StreetInsider.com
Fri, 11 Sep 2020
Is Soligenix’s (NASDAQ:SNGX) Share Price Gain Of 123% Well Earned? - Simply Wall St
Fri, 11 Sep 2020
SNGX: Update and Q&A on COVID-19 Vaccine Candidate CiVax™… - Yahoo Finance
Thu, 10 Sep 2020
Soligenix Announces Investor Webcast Event and Presentation Today: Advantages of the CiVax™ Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine - Yahoo Finance
Wed, 09 Sep 2020
Is Soligenix, Inc. Common Stock (SNGX) the Top Pick in the Biotechnology Industry? - InvestorsObserver
Thu, 03 Sep 2020
How Much Is Soligenix's (NASDAQ:SNGX) CEO Getting Paid? - Yahoo Finance
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
30 |
| Shares Float (M) |
30 |
|
% Held by Insiders
|
3.54 |
|
% Held by Institutions
|
8.83 |
|
Shares Short (K)
|
669 |
|
Shares Short P. Month (K)
|
659 |
Stock Financials |
|
EPS
|
-0.699 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
0.210 |
|
Profit Margin
|
|
|
Operating Margin
|
-515.24 |
|
Return on Assets (ttm)
|
-101.2 |
|
Return on Equity (ttm)
|
-330.0 |
|
Qtrly Rev. Growth
|
-67.3 |
|
Gross Profit (p.s.)
|
0.036 |
|
Sales Per Share
|
0.113 |
|
EBITDA (p.s.)
|
-0.580 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-9 |
|
Levered Free Cash Flow (M)
|
-9 |
Stock Valuations |
|
PE Ratio
|
-2.82 |
|
PEG Ratio
|
|
|
Price to Book value
|
9.38 |
|
Price to Sales
|
17.45 |
|
Price to Cash Flow
|
-6.50 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
